Inhibitor Therapeutics, Inc. (INTI)
USD 0.06
(20.0%)
USD 0.06
(20.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.4 Million USD | 417.53% |
| 2022 | 657.92 Thousand USD | 102.19% |
| 2021 | 325.39 Thousand USD | -69.27% |
| 2020 | 1.05 Million USD | -61.46% |
| 2019 | 2.74 Million USD | -39.8% |
| 2018 | 4.56 Million USD | -10.84% |
| 2017 | 5.11 Million USD | -27.1% |
| 2016 | 7.02 Million USD | 77.8% |
| 2015 | 3.94 Million USD | 0.3% |
| 2014 | 3.93 Million USD | 109.18% |
| 2013 | 1.88 Million USD | 235.76% |
| 2012 | 560.67 Thousand USD | -42.91% |
| 2011 | 982.09 Thousand USD | -4.32% |
| 2010 | 1.02 Million USD | -66.66% |
| 2009 | 3.07 Million USD | -34.89% |
| 2008 | 4.72 Million USD | 2.54% |
| 2007 | 4.61 Million USD | 124.61% |
| 2006 | 2.05 Million USD | -0.15% |
| 2005 | 2.05 Million USD | 19.62% |
| 2004 | 1.71 Million USD | 20.97% |
| 2003 | 1.42 Million USD | -3.99% |
| 2002 | 1.47 Million USD | -33.61% |
| 2001 | 2.22 Million USD | -24.45% |
| 2000 | 2.95 Million USD | -10.54% |
| 1999 | 3.29 Million USD | 9.95% |
| 1998 | 3 Million USD | 36.36% |
| 1997 | 2.2 Million USD | 214.29% |
| 1996 | 700 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 585.14 Thousand USD | -24.48% |
| 2024 Q1 | 774.81 Thousand USD | -39.15% |
| 2023 Q1 | 629.72 Thousand USD | 48.65% |
| 2023 Q3 | 759.52 Thousand USD | 2.3% |
| 2023 FY | 3.4 Million USD | 417.53% |
| 2023 Q4 | 1.27 Million USD | 67.64% |
| 2023 Q2 | 742.46 Thousand USD | 17.9% |
| 2022 FY | 657.92 Thousand USD | 102.19% |
| 2022 Q1 | 93.5 Thousand USD | 225.12% |
| 2022 Q3 | 69.98 Thousand USD | -1.15% |
| 2022 Q2 | 70.8 Thousand USD | -24.27% |
| 2022 Q4 | 423.63 Thousand USD | 505.31% |
| 2021 FY | 325.39 Thousand USD | -69.27% |
| 2021 Q1 | 167.75 Thousand USD | 200.97% |
| 2021 Q3 | 66.24 Thousand USD | 5.77% |
| 2021 Q2 | 62.63 Thousand USD | -62.66% |
| 2021 Q4 | 28.75 Thousand USD | -56.59% |
| 2020 Q3 | 302.77 Thousand USD | -3.89% |
| 2020 Q4 | 55.73 Thousand USD | -81.59% |
| 2020 Q2 | 315.04 Thousand USD | -18.26% |
| 2020 FY | 1.05 Million USD | -61.46% |
| 2020 Q1 | 385.44 Thousand USD | -39.57% |
| 2019 Q3 | 682.92 Thousand USD | 7.46% |
| 2019 Q1 | 791.6 Thousand USD | -40.46% |
| 2019 FY | 2.74 Million USD | -39.8% |
| 2019 Q4 | 637.87 Thousand USD | -6.6% |
| 2019 Q2 | 635.5 Thousand USD | -19.72% |
| 2018 Q4 | 1.32 Million USD | 13.1% |
| 2018 FY | 4.56 Million USD | -10.84% |
| 2018 Q3 | 1.17 Million USD | 32.92% |
| 2018 Q2 | 884.4 Thousand USD | -24.72% |
| 2018 Q1 | 1.17 Million USD | 29.76% |
| 2017 Q4 | 905.35 Thousand USD | 32.91% |
| 2017 FY | 5.11 Million USD | -27.1% |
| 2017 Q1 | 2.81 Million USD | 1.79% |
| 2017 Q3 | 681.16 Thousand USD | -5.32% |
| 2017 Q2 | 719.43 Thousand USD | -74.43% |
| 2016 FY | 7.02 Million USD | 77.8% |
| 2016 Q4 | 2.76 Million USD | 59.35% |
| 2016 Q3 | 1.73 Million USD | 30.38% |
| 2016 Q2 | 1.33 Million USD | 11.35% |
| 2016 Q1 | 1.19 Million USD | 15.61% |
| 2015 Q2 | 791.65 Thousand USD | -14.2% |
| 2015 Q3 | 1.2 Million USD | 51.84% |
| 2015 Q4 | 1.03 Million USD | -14.05% |
| 2015 FY | 3.94 Million USD | 0.3% |
| 2015 Q1 | 922.67 Thousand USD | 2.85% |
| 2014 Q4 | 897.13 Thousand USD | 21.55% |
| 2014 Q2 | 2.11 Million USD | 1031.79% |
| 2014 Q3 | 738.09 Thousand USD | -65.11% |
| 2014 FY | 3.93 Million USD | 109.18% |
| 2014 Q1 | 186.93 Thousand USD | -12.34% |
| 2013 Q3 | 1.29 Million USD | 351.5% |
| 2013 Q4 | 213.24 Thousand USD | -83.5% |
| 2013 Q2 | 286.25 Thousand USD | 216.15% |
| 2013 Q1 | 90.54 Thousand USD | -56.2% |
| 2013 FY | 1.88 Million USD | 235.76% |
| 2012 Q4 | 206.74 Thousand USD | 50.39% |
| 2012 Q3 | 137.46 Thousand USD | 23.37% |
| 2012 Q2 | 111.42 Thousand USD | 6.08% |
| 2012 Q1 | 105.03 Thousand USD | -75.53% |
| 2012 FY | 560.67 Thousand USD | -42.91% |
| 2011 Q4 | 429.18 Thousand USD | 204.1% |
| 2011 Q3 | 141.13 Thousand USD | -19.02% |
| 2011 Q1 | 237.51 Thousand USD | 123.85% |
| 2011 Q2 | 174.27 Thousand USD | -26.63% |
| 2011 FY | 982.09 Thousand USD | -4.32% |
| 2010 Q1 | 778.73 Thousand USD | 28.42% |
| 2010 FY | 1.02 Million USD | -66.66% |
| 2010 Q4 | -995.93 Thousand USD | -273.44% |
| 2010 Q3 | 574.23 Thousand USD | -14.22% |
| 2010 Q2 | 669.41 Thousand USD | -14.04% |
| 2009 FY | 3.07 Million USD | -34.89% |
| 2009 Q4 | 606.41 Thousand USD | -34.94% |
| 2009 Q3 | 932.07 Thousand USD | 21.27% |
| 2009 Q2 | 768.59 Thousand USD | -0.41% |
| 2009 Q1 | 771.77 Thousand USD | -25.62% |
| 2008 FY | 4.72 Million USD | 2.54% |
| 2008 Q2 | 1.14 Million USD | -21.82% |
| 2008 Q1 | 1.46 Million USD | 42.81% |
| 2008 Q4 | 1.03 Million USD | -18.6% |
| 2008 Q3 | 1.27 Million USD | 11.55% |
| 2007 FY | 4.61 Million USD | 124.61% |
| 2007 Q3 | 1.56 Million USD | -32.08% |
| 2007 Q2 | 2.3 Million USD | 215.92% |
| 2007 Q1 | 730.31 Thousand USD | 47.19% |
| 2007 Q4 | 1.02 Million USD | -34.68% |
| 2006 Q4 | 496.17 Thousand USD | -2.59% |
| 2006 Q3 | 509.36 Thousand USD | 0.91% |
| 2006 FY | 2.05 Million USD | -0.15% |
| 2006 Q2 | 504.75 Thousand USD | -7.02% |
| 2006 Q1 | 542.88 Thousand USD | 15.07% |
| 2005 Q2 | 440.86 Thousand USD | -19.27% |
| 2005 Q1 | 546.08 Thousand USD | 2.11% |
| 2005 Q3 | 617.37 Thousand USD | 40.04% |
| 2005 Q4 | 471.78 Thousand USD | -23.58% |
| 2005 FY | 2.05 Million USD | 19.62% |
| 2004 Q1 | 384.97 Thousand USD | 14.32% |
| 2004 FY | 1.71 Million USD | 20.97% |
| 2004 Q3 | 402.01 Thousand USD | 1.24% |
| 2004 Q4 | 534.79 Thousand USD | 33.03% |
| 2004 Q2 | 397.09 Thousand USD | 3.15% |
| 2003 Q2 | 382.88 Thousand USD | 12.37% |
| 2003 Q1 | 340.75 Thousand USD | -18.35% |
| 2003 Q3 | 360.47 Thousand USD | -5.85% |
| 2003 FY | 1.42 Million USD | -3.99% |
| 2003 Q4 | 336.76 Thousand USD | -6.58% |
| 2002 FY | 1.47 Million USD | -33.61% |
| 2002 Q3 | 327.14 Thousand USD | -18.88% |
| 2002 Q4 | 417.33 Thousand USD | 27.57% |
| 2002 Q2 | 403.26 Thousand USD | 21.38% |
| 2002 Q1 | 332.23 Thousand USD | -38.64% |
| 2001 Q3 | 469.78 Thousand USD | -20.96% |
| 2001 Q1 | 623.71 Thousand USD | -32.37% |
| 2001 FY | 2.22 Million USD | -24.45% |
| 2001 Q4 | 541.44 Thousand USD | 15.25% |
| 2001 Q2 | 594.36 Thousand USD | -4.71% |
| 2000 FY | 2.95 Million USD | -10.54% |
| 2000 Q4 | 922.3 Thousand USD | 23.63% |
| 2000 Q3 | 746 Thousand USD | 1.96% |
| 2000 Q2 | 731.69 Thousand USD | 33.58% |
| 2000 Q1 | 547.75 Thousand USD | -39.04% |
| 1999 Q3 | 700 Thousand USD | -22.22% |
| 1999 FY | 3.29 Million USD | 9.95% |
| 1999 Q2 | 900 Thousand USD | 12.5% |
| 1999 Q4 | 898.51 Thousand USD | 28.36% |
| 1999 Q1 | 800 Thousand USD | 0.0% |
| 1998 Q3 | 800 Thousand USD | 14.29% |
| 1998 Q2 | 700 Thousand USD | 0.0% |
| 1998 Q1 | 700 Thousand USD | -22.22% |
| 1998 FY | 3 Million USD | 36.36% |
| 1998 Q4 | 800 Thousand USD | 0.0% |
| 1997 FY | 2.2 Million USD | 214.29% |
| 1997 Q4 | 900 Thousand USD | 50.0% |
| 1997 Q3 | 600 Thousand USD | 225.32% |
| 1997 Q1 | -478.78 Thousand USD | 0.0% |
| 1997 Q2 | -478.78 Thousand USD | 0.0% |
| 1996 FY | 700 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -154.972% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 32.468% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 88.478% |
| Nascent Biotech, Inc. | 2.22 Million USD | -52.698% |
| Rebus Holdings, Inc. | 664 Thousand USD | -412.798% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 90.861% |
| Qrons Inc. | 643.67 Thousand USD | -428.989% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -774.044% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.072% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -719.531% |
| Skye Bioscience, Inc. | 13.54 Million USD | 74.866% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.077% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 30.764% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1200.971% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.023% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -16.759% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -126.712% |
| Mesoblast Limited | 5.9 Million USD | 42.308% |
| Marizyme, Inc. | 19.23 Million USD | 82.302% |
| Genus plc | 147.7 Million USD | 97.695% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 61.216% |
| Pharming Group N.V. | 225.49 Million USD | 98.49% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -66.202% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -153.81% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 59.168% |
| ContraFect Corporation | 56.88 Million USD | 94.015% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 22.766% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -130.26% |
| IMV Inc. | 37.7 Million USD | 90.97% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -22.027% |
| MultiCell Technologies, Inc. | 567.42 USD | -599980.892% |
| ONE Bio Corp. | 6.44 Million USD | 47.16% |
| Accustem Sciences Inc. | 3.74 Million USD | 9.114% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.038% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -540.079% |
| Q BioMed Inc. | 3.43 Million USD | 0.921% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 86.223% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -29.589% |
| Biomind Labs Inc. | 994.18 Thousand USD | -242.491% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.572% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -93.5% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 49.316% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -82.634% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13719.916% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 78.732% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -85.548% |
| GB Sciences, Inc. | 1.42 Million USD | -139.701% |
| Alpha Cognition Inc. | 9.7 Million USD | 64.917% |
| HST Global, Inc. | 140.9 Thousand USD | -2316.473% |
| CSL Limited | 3.44 Billion USD | 99.901% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -202.689% |
| Halberd Corporation | 74.84 Thousand USD | -4449.556% |
| Enzolytics Inc. | 2.17 Million USD | -56.227% |
| Agentix Corp. | 1.37 Million USD | -148.22% |
| Resverlogix Corp. | 12.71 Million USD | 73.214% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 6.731% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.778% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -226.147% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -41.583% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -115.593% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | 53.422% |
| Zenith Capital Corp. | 8.94 Million USD | 61.926% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.587% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -19445.256% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -38.678% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1885.306% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -77.259% |
| Kadimastem Ltd | 2.41 Million USD | -41.279% |
| Helix BioMedix, Inc. | 1.97 Million USD | -72.663% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 68.667% |
| BioStem Technologies, Inc. | 22.97 Million USD | 85.18% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1776.177% |
| LadRx Corporation | 3.81 Million USD | 10.672% |
| Cell Source, Inc. | 4.32 Million USD | 21.278% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -268.7% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -268.7% |
| NovAccess Global Inc. | 2.46 Million USD | -38.034% |
| Affymax, Inc. | 39.38 Million USD | 91.355% |
| Itoco Inc. | 919.14 Thousand USD | -270.451% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 19.664% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -204.288% |
| Mobile Lads Corp. | 554.54 Thousand USD | -514.012% |
| CytoDyn Inc. | 18.05 Million USD | 81.144% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13428.464% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1447.169% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -139.822% |
| SYBLEU INC | 160.87 Thousand USD | -2016.524% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -87.466% |
| International Stem Cell Corporation | 5.27 Million USD | 35.402% |
| Bioxytran, Inc. | 3.82 Million USD | 10.868% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6368.179% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -16637.841% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 90.611% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -110.444% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -362.737% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -9.45% |
| Neutra Corp. | 243.82 Thousand USD | -1296.508% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 80.495% |
| PureTech Health plc | 144.59 Million USD | 97.645% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 83.382% |
| IXICO plc | 4.7 Million USD | 27.661% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 61.294% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.108% |
| CSL Limited | 3.89 Billion USD | 99.913% |
| Cellectis S.A. | 97.32 Million USD | 96.501% |